Description

This grant opportunity from Alnylam Pharmaceuticals aims to support innovative, independent educational projects that address gaps in the screening, diagnosis, monitoring, and management of transthyretin-mediated amyloidosis (ATTR-CM). The primary focus is on equipping clinicians with actionable information and practical tools to improve real-world clinical decision-making and patient outcomes. Funded activities should be evidence-based, fair, and balanced, and designed for practical application in routine healthcare settings. Proposals may target U.S. and/or global audiences, with particular emphasis on specialists such as cardiologists and clinical pharmacists involved in ATTR-CM management.